



04-20-00

Serle Ian Mosoff
Attorney At Law

Law Offices at Sound Shore
303 Boston Post Road
Port Chester, NY 10573

Direct Dial (914) 934-7753
(914) 939-1300

Fax (914) 934-7653

Email pcounsel@usa.pipeline.com



Spetember 18, 2000

Honorable Commissioner of Patents and Trademarks
Washington, D. C. 20231

Sir:

Transmitted herewith is the patent application of:

Inventors: Ansley, Daniel R. and Willeford, Kenneth O.
For: Composition and Method for Immunomodulation in Non-Mammalian Vertebrates

Enclosed are:

- | | |
|-------------------------------------|--|
| <input checked="" type="checkbox"/> | 4 sheets of drawings |
| <input type="checkbox"/> | an assignment of the invention |
| <input type="checkbox"/> | a certified copy of the application |
| <input type="checkbox"/> | an associate power of attorney |
| <input checked="" type="checkbox"/> | a verified statement to establish Small Entity status under 37 CFR §1.9 and §1.27 is enclosed. |


The fee has been calculated as follows

	Number of Claims Filed	Extra Claims	Rate	Fee
Basic Fee	8		\$345	\$345
Total Claims	8 - 20 = 0	0	x9	0
Independent claims	1 - 3 = 0	0	x39	0
() Multiple dependent Claims Presented			+\$115	
		Total Fee		\$345

☐ also included is the \$40 fee for assignment recordal.

☐ charge deposit account ---- in the amount of _____
☒ a check in the amount of \$ 345 is enclosed.

A triplicate copy of this paper is enclosed.


Serle Ian Mosoff
Reg. No. 25,900

Stamp: RECEIVED
EF04139794405
19 Sep 00
Asst.
19 Sept 00

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Ansley, Daniel R. and Willeford, Kenneth O.

Group Art Unit:

Serial No.:

Examiner:

Filed: Herewith

For: Composition And Method For Immunomodulation In Non-Mammalian Vertebrates

VERIFIED STATEMENT (DECLARATION) CLAIMING SMALL ENTITY STATUS (37 CFR §1.9(f) AND §1.27(b)) - INDEPENDENT INVENTOR

As a below named inventor, I hereby declare that I qualify as an independent inventor as defined in 37 CFR §1.9(c) for purposes of paying reduced fees under section 41(a) and (b) of Title 35, United States Code, to the Patent and Trademark Office with regard to the invention entitled COMPOSITION AND METHOD FOR IMMUNOMODULATION IN NON-MAMMALIAN VERTEBRATES and described in

☒ the specification filed herewith.
☐ application serial no.
☐ patent no. , issued

I have not assigned, conveyed or licensed and am under no obligation under contract or law to assign, grant, convey or license, any rights in the invention to any person who could not be classified as an independent inventor under 37 CFR §1.9(c) if that person had made the invention, or to any concern which could not qualify as a small business concern under 37 CFR §1.9(d) or a nonprofit organization under 37 CFR §1.9(e).

Each person, concern or organization to which I have assigned, granted, conveyed, or licensed or am under an obligation under contract or law to assign, grant, convey or license any rights to my invention is listed below*

*NOTE Separate verified statements are required from each named person, concern or organization having rights to the invention averring to their status as small entities. (37 CFR §1.27)

Full Name _____

Address _____

☐ individual☐ small business concern☐ nonprofit organization

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting from loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. (37 CFR §1.28(b))

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this verified statement is directed.

Daniel R. Ansley

Kenneth O. Willeford

Name Of First Inventor

Name Of Second Inventor

Name Of Third Inventor

Signature Of First Inventor

Signature Of Second Inventor

Signature Of Third Inventor

Date

Date

Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Ansley, Daniel R. and Willeford, Kenneth O.

Group Art Unit:

Serial No.:

Examiner:

Filed: Herewith

For: Composition And Method For Immunomodulation In Non-Mammalian Vertebrates

VERIFIED STATEMENT (DECLARATION) CLAIMING SMALL ENTITY STATUS (37 CFR §1.9(f) AND §1.27(b)) - INDEPENDENT INVENTOR

As a below named inventor, I hereby declare that I qualify as an independent inventor as defined in 37 CFR §1.9(c) for purposes of paying reduced fees under section 41(a) and (b) of Title 35, United States Code, to the Patent and Trademark Office with regard to the invention entitled COMPOSITION AND METHOD FOR IMMUNOMODULATION IN NON-MAMMALIAN VERTEBRATES and described in

☒ the specification filed herewith.
☐ application serial no.
☐ patent no. , issued

I have not assigned, conveyed or licensed and am under no obligation under contract or law to assign, grant, convey or license, any rights in the invention to any person who could not be classified as an independent inventor under 37 §CFR 1.9(c) if that person had made the invention, or to any concern which could not qualify as a small business concern under 37 CFR §1.9(d) or a nonprofit organization under 37 CFR §1.9(e).

Each person, concern or organization to which I have assigned, granted, conveyed, or licensed or am under an obligation under contract or law to assign, grant, convey or license any rights to my invention is listed below*

*NOTE Separate verified statements are required from each named person, concern or organization having rights to the invention averring to their status as small entities. (37 CFR §1.27)

Full Name

Address

[] individual [] small business concern [] nonprofit organization

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting from loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. (37 CFR §1.28(b))

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this verified statement is directed.

Daniel R. Ansley

Kenneth O. Willeford

Name Of First Inventor

Name Of Second Inventor

Name Of Third Inventor



Signature Of First Inventor

Signature Of Second Inventor

Signature Of Third Inventor

9-1-2000

Date

Date

Date

09565009-091500

1 COMPOSITION AND METHOD FOR IMMUNOSTIMULATION IN NON-
2 MAMMALIAN VERTEBRATES

3
4 Background of the Invention

5 It has long been known that mammals, when confronted with bacterial or viral
6 infections, exhibit efforts at self-healing which are initiated by a complex physiological
7 network referred to as the immune system. The immune system operates in response to a
8 challenge to the mammal by initially recognizing the presence of a foreign organism or
9 pathogen within the animal's body. In mammals, this is followed by an attack on the
10 foreign organism by the neutrophils, macrophages and other "killer" cells of the immune
11 system. This immune response functions or is "turned on" by a variety of immune system
12 regulators which activate the various aspects of the immune system depending upon the
13 type of insult confronting the subject animal.

14 A substantial component of the immune system is a group of structurally related
15 glycoproteins, collectively known as immunoglobulins, contained within blood and extra
16 cellular fluids. Five immunoglobulin classes have been identified: immunoglobulin G (IgG),
17 IgM, IgA, IgD and IgE. The basic structural unit of each immunoglobulin class consists of
18 two pairs of polypeptide chains joined by disulfide bonds. The five classes of
19 immunoglobulins have different biological properties and different distributions in the
20 body. The structure responsible for the biological properties of each immunoglobulin class
21 is located on that part of the immunoglobulin molecule which is unique for each class--the
22 Fc fragment. While some antibodies are produced at all times in normal animals, other
23 antibodies are produced only in response to specific antigenic stimulation (e.g., when
24 pathogenically challenged).

25 IgG is the major antibody class in normal mammalian systems and forms about 70%
26 of the total immunoglobulin. IgG is evenly distributed between intra- and extra vascular
27 pools. It is the first major antibody of the secondary immune response and belongs to the
28 exclusive antitoxin class. IgG is a monomeric protein which can be divided into four sub-
29 chains--two heavy chains "H" and two light chains "L". Taking the four sub-chains
30 together each IgG molecule consists of one H₂L₂ unit with a molecular weight of
31 approximately 140,000 Daltons. Molecules of the IgG class are actively transported across

1 the placenta and provide passive immunity to newborns at a time when the infant's immune
2 mechanisms are not developed.

3 The remaining four immunoglobulin classes are more narrow components of the
4 immune system.

5 IgM is the first immunoglobulin class produced by the maturing fetus. IgM does
6 not normally cross the placenta from the mother to fetus, but may be produced actively by
7 the fetus prior to birth, especially if the fetus has been exposed to antigens by infection.
8 IgA is found in relatively small amounts in serum and tissue fluids, but is present in high
9 concentrations in external secretion such as saliva, tears, and bronchial secretions. IgE is
10 also present in very low concentrations and appears to be associated with the histamine
11 response. The last immunoglobulin class, IgD, is present in very low concentrations in
12 secretions. IgD stimulates immature lymphocytes to multiply and differentiate thereby
13 causing the production and secretion of other antibodies. Therefore, all immunoglobulin
14 classes are important in immune system responses.

15 Modulation of the immune system to effect greater response to foreign agents has
16 been an area of interest for some years. The development of specific antibodies through
17 vaccination has long been utilized to provide mammals with long term immune defense
18 mechanisms to specific microorganism forms.

19 Ansley, USP 5,219,578, June 15, 1993 discloses a non-adjuvanted IgG containing
20 caprine serum fraction. This fraction is useful as an immunostimulant in mammals when
21 challenged by specified diseases.

22 Recent efforts in immunology have been directed towards the utilization of immune
23 system regulating molecules, rather than one of the five classes of immunoglobulins, to
24 provide increased immune system activity. It is believed that, through the use of immune
25 regulating or immune modulating molecules, a state of general immune system hyperactivity
26 can be induced which may help combat challenges to the immune system (e.g., pathogenic
27 infection). Infection may arise from a wound site or may arise from an opportunistic
28 blooming when the host organism is simply deprived of sufficient sleep. It is believed that
29 an induced state of general immune hyperactivity would result in a therapeutic response to
30 the challenge. This might be viewed as the opposite of the vaccination type response that
31 produces a specific long-term immunity. If such a non-specific immune response could be

1 initiated at will it could be utilized to either act alone or in conjunction with a conventional
2 treatment directed towards the etiological agents.

3 Such a mechanism could be based upon activation of phagocytic cells that are
4 capable of responding to a wide range of infectious agents. It may also be that the T-
5 lymphocytes, which are major mediators of the overall immune response, may act to
6 enhance the operation of non-specific cellular immunity even though the T-lymphocytes
7 themselves are a part of the specific immune response.

8 The search for agents which potentiate the immune response is a driving force in
9 drug research. Cytokines and cationic peptides are two classes of "relatively" low molecular
10 weight compounds which have shown promise in this area of research. At least nine
11 immuno-defense peptide products are commercially available with annual sales of over \$4
12 billion (Latham, P.W., 1999, Therapeutic peptides revisited, *Nature Biotechnology* 17:755-757).

13 Bio-active peptides (such as "cationic peptides") are emerging as promising
14 alternatives for combating antibiotic-resistant bacteria with minimum inhibitory
15 concentrations reported from 1-100 µg/ml (Martin, E., T. Ganz, and R.I. Lehrer, 1995.
16 Defensins and other endogenous peptide antibiotics of vertebrates, *J. Leukoc. Biol.*, 58:128-
17 136; Hancock, R. E. W., 1997, Peptide antibiotics, *Lancet*, 349:418-422). Cationic peptides
18 range from 16-18 amino acid residues for the protegrins (Ganz, T., and R. Lehrer, 1998.
19 Antimicrobial peptides of vertebrates, *Curr. Opin. Immunol.*, 10:41-44.) to 29-35 residues for
20 mammalian defensins (Sawa, T., and K. Turahashi, 1999, Antimicrobial peptides/proteins -
21 application to the therapy of sepsis (article in Japanese), *Masui*, 48:1186-1193.). Due to a
22 compositional prominence of lysine and arginine, they possess a net positive charge of at
23 least 2, and usually 4, 5, or 6 (Hancock, R. E. W., 1997, Peptide antibiotics, *Lancet*, 349:418-
24 422).

25 Interleukin-1 (IL-1), tumor necrosis factor- α (TNF- α) and interferon (IFN) are
26 three cytokines which participate in the immune response. IL-1 is involved in the host's
27 response to antigenic challenge and tissue injury, and has been shown to increase the
28 resistance of mice to pathogenic organisms such as *Listeria*, *Escherichia coli*, and *Candida*
29 *albicans* (Czuprynski, C.J., and Brown, J.F., 1987, Recombinant murine interleukin-1 α
30 enhancement of nonspecific antibacterial resistance, *Infection and Immunity* 55:2061-2065;
31 Cross, A.S., Sadoff, J.C., Kelly, N, Bernton, F., and Gemski, P., 1989, Pretreatment with
32 recombinant murine tumor necrosis factor α /cachectin and murine interleukin 1 α protects

LAW OFFICES OF

SERLE IAN MOSOFF
303 BOSTON POST ROAD
PORT CHESTER, NEW YORK 10573
(914) 939-1300

1 mice from lethal bacterial infection, *The Journal of Experimental Medicine* 169:2021-2027; Pecyk,
 2 R.A., Fraser-Smith, E.B., and Matthews, T.R., 1989, Efficacy of interleukin-1 β against
 3 systemic *Candida albicans* in normal and immunosuppressed mice, *Infection and Immunity*
 4 57:3257-3258.). TNF- α and γ -IFN were able to increase the resistance of mice to *Salmonella*
 5 *typhimurium* (Morrissey, P.J., and Charrier, K., 1994, Treatment of mice with IL-1 before
 6 infection with increases resistance to a lethal challenge with *Salmonella typhimurium*, *The Journal*
 7 *of Immunology* 153:212-219). Human α IFN's have potent antiviral and antiproliferative
 8 activities, and are currently being utilized as anticancer or antiviral therapeutic agents
 9 (Chang, C.J., Chen, T.T., Cox, B.W., Dawes, G.N., Stemmer, W., Punnonen, J., and Patten,
 10 P.A., 1999, Evolution of a cytokine using DNA family shuffling, *Nature Biotechnology* 17:793-
 11 797).

12 Cationic peptides help defend against the constant assault of moderate numbers of
 13 bacteria. Each natural peptide has a broad but incomplete spectrum of activity. The host
 14 compensates for this by producing an array of different peptides that together have a
 15 broader spectrum of activity, and often work in synergy with one another. A single
 16 individual may produce dozens of different peptides and more than 500 natural cationic
 17 peptides have been discovered (Hancock, R. E. W., 1999. Host defence (cationic) peptides,
 18 *Drugs* 57:469-473).

19 Bio-active peptides have been found to possess antiviral, antibacterial, antifungal,
 20 and wound healing properties (Sanglier, J., Haag, H., Huck, T., and Fehr, T., 1993. Novel
 21 bioactive components from Actinomycetes: A short review (1988-1992), *Res. Microbiol.*
 22 144:633-642; Mizuno, T., Wang, G., Zhang, J., Kawagishi, H., Nishitoba, T., and Li, J., 1995;
 23 Reishi, *Ganoderma Lucidum* and *Ganoderma Tsugae*: Bioactive substances and medicinal effects,
 24 *Food Rev. Int.* 11:151-166; Hancock, R. E. W., 199, Host defence (cationic) peptides, *Drugs*
 25 57:469-473). A decameric peptide has even been shown to impede the growth and spread
 26 of established tumors (Folkman, J., 1999, Angiogenic zip code, *Nature Biotechnology* 17:749).
 27 It is believed that these "defense" peptides are more general in action than antibodies, and
 28 as such, have a broader range of activity (Hancock, 1999). These peptides have low toxicity
 29 to most mammalian cells and are therefore candidate for development as therapeutic agents
 30 (Maloy, W.L., and U.P. Kari, 1995. Structure-activity studies on magainins and other host
 31 defense peptides, *Biopolymers (Peptide Science)*, 37:105-122).

1 Industrially raised non-mammalian food animals such as chickens and turkeys are
2 subjected to high stress and are more susceptible to disease than free range animals. It is
3 common to provide such non-mammalian vertebrates with prophylactic amounts of various
4 antibiotics and other disease preventative drugs to minimize disease related losses.

5 Non-mammalian species used as food animals are subjected to high stress levels
6 during shipment to processing centers and while awaiting processing. Disease is common
7 during such periods of stress.

8 More exotic animals, such as those kept in zoos, are subject to stress related and
9 stress non-related diseases due to the artificial environments in which they live. A
10 nonspecific immunostimulant would be desirable for both prophylactic and ameliorative
11 purposes.

12 The cost associated with the administration of prophylactic agents and the inherent
13 risk of residues of such drugs remaining in the edible portions of the food animal make it
14 desirable to minimize the administration of such drugs. A simple and elegant means of
15 accomplishing this is to increase the assertiveness of the non-mammalian vertebrate's own
16 disease fighting systems.

17 Therefore, it is an object of the present invention to provide a means for
18 modulating the immune response in non-mammalian vertebrates afflicted with disease.

19 Another object of the present invention is to provide a means for enhancing the
20 ability of conventional anti-microbial medicaments by providing a concomitant stimulation
21 of the animal's immune response.

22 Yet another object of the present invention is to provide a means of stimulating the
23 immune response in non-mammalian vertebrates to heighten the animal's ability at self-
24 healing when challenged by an infectious agent.

25 Yet another object of the present invention is to provide a means of
26 prophylactically stimulating the immune response in non-mammalian vertebrates to
27 heighten the animal's ability to avoid disease prior to being placed in a high stress
28 environment.

29 The above and further objects and novel features of the invention will more fully
30 appear from the following description and the examples contained therein.

LAW OFFICES OF

SERLE IAN MOSOFF
303 BOSTON POST ROAD
PORT CHESTER, NEW YORK 10573
(914) 939-1300

1

2 Brief Description of the Drawings

3 Figure 1 represents the results obtained when chickens were injected with 30 cfu of
4 *Pasteurella multocida* on day 0 (open) and 5 mg of CSF-I2 on days -1 and 0 (hatched).
5 Mortality was monitored daily for one week. Each bar represents the average mortality per
6 cage (n = 3) of 10 birds with its associated standard experimental error.

7 Figure 2 represents the results obtained when chickens were injected with 18 cfu of
8 *Pasteurella multocida* on day 0 (open) and 10 mg of CSF-I2 on days -1 and 0 (hatched).
9 Mortality was monitored daily for one week. Each bar represents the average mortality per
10 cage (n = 5) of 6 birds with its associated standard experimental error.

11 Figure 3 represents the results obtained when chickens were injected with 28 cfu of
12 *Pasteurella multocida* on day 0 (open) and 10 mg of CSF-I2 on days -1, 0, and 1 (hatched).
13 Mortality was monitored daily for one week. Each bar represents the average mortality per
14 cage (n = 5) of 12 birds with its associated standard experimental error.

15 Figure 4 represents the results obtained when the percent mortality of CSF-I2
16 treated chickens was subtracted from its associated control group's mortality for each
17 treatment regime: 5 mg CSF-I2 (i.m., days -1 and 0), (●); 10 mg CSF-I2 (i.m., days -1 and
18 0), (▲); and 10 mg CSF-I2 (i.m., days -1, 0, and 1), (■).

19 Summary Of The Invention

20 The present invention is broadly concerned with a unique method for cross species
21 modulation of the immune system. Surprisingly, we have now determined that substantially
22 immunoglobulin free material fractionated from mammalian serum, preferably goat serum,
23 helps retard pathogenesis in non-mammalian vertebrate species.

24 The inventive method and inventive compounds derived thereby involve, generally,
25 the isolation of a low molecular weight substantially immunoglobulin free fraction from the
26 blood of a mammal. This mammal has not been pre-treated in any way nor have foreign
27 antigens been artificially introduced to the mammal. The substantially immunoglobulin free
28 fraction obtained from this mammal is then used to treat a non-mammalian vertebrate. The
29 non-mammalian vertebrate can be any vertebrate species, such as birds, reptiles or fish.

1 Treatment of the non-mammalian vertebrate with the substantially immunoglobulin
2 free fraction from the mammal stimulates the disease fighting systems of the non-
3 mammalian vertebrate. The non-mammalian vertebrate is thereby assisted in overcoming
4 the deleterious effects of a disease or malady.

5 Detailed Description

6 We have now determined that material fractionated from mammalian serum,
7 preferably goat serum, helps retard pathogenesis in non-mammalian vertebrates, supporting
8 the belief that the substantially immunoglobulin free fraction is non-specific species
9 independent.

10 Agents which retard pathogenesis may enable a host to mount a successful defense
11 to challenges of the immune system. These agents can provide specific protection (i.e., in
12 the form of antibodies) or be general in nature and enhance the overall immuno-response.
13 Cytokines and cationic peptides are two such classes of non-specific defense agents.

14 The product of this invention is a non-adjuvanted stimulant of the animal's disease
15 fighting systems. It is derived from mammalian serum and contains a mixture of serum
16 proteins and peptides but is substantially free of immunoglobulins. The mammalian species
17 is preferably one from which relatively large quantities of blood may be drawn. It is
18 convenient to use large animals to obtain greater quantities of serum. It is convenient to use
19 domestic animals as they are readily available. Thus, convenient species are horses, cows,
20 goats, sheep and pigs. Horses, cows and goats are preferred sources; goats are the most
21 preferred serum source.

22 Albumin and immunoglobins (the two most abundant serum proteins) have
23 molecular weights in the range of 66,000 to 155,000 daltons. The product of this invention
24 is preferably produced utilizing a size fractionation procedure to remove proteins and other
25 molecules having a molecular weight greater than 60,000 daltons, preferably greater than
26 25,000 daltons, most preferably greater than 8,000 daltons. Therefore, the product is
27 substantially if not completely free of immunoglobulin, albumin, and most cytokines.

28 The mammalian serum suitable for use in the invention is obtained from any
29 convenient species of mammal. The collected serum is treated to separate it into high and
30 low molecular weight fractions. A convenient cut-off point for the separation is in the range
31 of 6000 - 8000 daltons although any cut-off point which effectively excludes

1 immunoglobulins is acceptable. The primary requirement is that the fractionation remove
2 substantially all immunoglobulins and albumin present from the low molecular weight
3 fraction.

4 The serum may be fractioned by collecting the material which flows through a
5 dialysis membrane possessing the desired molecular weight cut-off range. Spectra Por™
6 dialysis membranes with appropriate cut-off limits have been used successfully in preparing
7 the products of this invention. Alternative fractionation procedures may also be used,
8 provided that they remove serum fractions having a molecular weight cut-off of over 60,000
9 daltons, preferably over 25,000 daltons, most preferably over 8,000 daltons, and do not
10 denature the peptides in the low molecular weight portion.

11 The low molecular weight material obtained from the fractionation process may be
12 used immediately or it may be held for future use. If held for future use it is conveniently
13 lyophilized to a powder and stored at -70° C, until reconstituted with water for use. A
14 typical fraction derived from goat serum has a proteinaceous content of 35 % - 40 % based
15 on an analysis of its nitrogen content.

16 The non-specific immunostimulant of this invention may be used to protect non-
17 mammalian vertebrates against the onset of diseases or may be utilized to ameliorate the
18 effect of diseases after they begin.

19 The immunomodulator provides useful protective properties in various genera of
20 non-mammalian vertebrates. It can provide prophylactic or curative effects against such
21 diseases as infection with *Pasturella* in birds.

22 The treatment regime will vary with the animal and purpose of administration.
23 Dosage amounts depend on the size of the animal being treated and range from a minimum
24 of about 5 mg, preferably about 10 mg in avians. A second dose of the same size is typically
25 administered between 1 and 3 days after the first dose.

26 The material may be administered alone, in conjunction with, at the same time as, or
27 shortly before or after other treatments.

28 The material may be administered by any convenient route, such as intramuscularly,
29 subcutaneously, intravenously or intraperitoneally. Topical administration, with a suitable
30 adjuvant such as DMSO, is also effective against certain conditions. Oral administration is
31 of particular usefulness for birds or other small or non-domesticated animals.

1 This low molecular weight material (hereafter referred to as CSF-I2) was subjected
2 to testing to determine its ability to prevent the growth of bacteria. The results obtained
3 show that the material is unable to inhibit growth of gram-negative or gram-positive
4 bacteria.

5 The minimum inhibitory concentration (MIC) for a cationic peptide is usually in the
6 range of 1 to 8 µg/mL (Hancock, R.E.W., 1997. Peptide antibiotics. *The Lancet*, 349:418-
7 422). Two serotypes of *Pasteurella* showed no zone of growth inhibition when CSF-I2 was
8 tested at 20 mg/mL, over 2,500 times the upper MIC range recognized for cationic
9 peptides, however, the product was able to inhibit *Pasteurella* pathogenesis in avian studies.

10 The material has been tested in non-mammalian vertebrates and has been
11 determined to be effective in lessening or curing various diseases either when used alone or
12 in conjunction with standard therapies. It has demonstrated effectiveness in avians against
13 severe bacterial infection.

14 An animal model was established which permits the accurate assessment within a 2
15 day period of the immuno-activity present in CSF-I2, the material fractionated from caprine
16 serum, against specific microbial challenges. Because the agent present in CSF-I2
17 significantly reduced specific-pathogen-free chicken mortality given a severe microbial
18 challenge, it is possible that the immuno-active components may offer even a higher degree
19 of protection against less virulent pathogenic challenges. The mechanism by which CSF-I2
20 precipitates its immuno-effect is unclear. Nevertheless, the evidence suggests that one
21 possible route by which CSF-I2 sustains an immuno-competent status is by maintaining or
22 increasing the CD4 population and reducing the CD8 cell population.

23 EXAMPLE

24 To determine the level of effectiveness of the low molecular weight compositions of
25 this invention in ameliorating disease states in non-mammalian vertebrates, chickens were
26 pathogenically challenged.

27 Specific-Pathogen-Free (SPF) layer chickens experience a severe rate of mortality
28 when challenged by low doses (18 to 30 CFUs) of *P. multocida* X-73 (serotype 1). CSF-I2
29 was, however, able to significantly retard *Pasteurella* pathogenesis and promote higher
30 survivability in SPF chickens. Three treatment regimes of CSF-I2 were examined in this
31 study: 5 mg CSF-I2 (i.m., days -1 and 0), 10 mg CSF-I2 (i.m., days -1 and 0), and 10 mg

LAW OFFICES OF

SERLE IAN MOSOFF
303 BOSTON POST ROAD
PORT CHESTER, NEW YORK 10573
(914) 939-1300

CSF-I2 (i.m., days -1, 0, and 1), where day 0 represents the day of challenge. All treatments effectively reduced mortality through 1 week post-challenge. The 10 mg CSF-I2 dose regimes, however, clearly performed better than the 5 mg CSF-I2 dose regime. A statistical comparison between the two 10 mg CSF-I2 dose regimes was not made. However, there was no evidence that Day 1 administration of CSF-I2 improved survivability.

Animal Husbandry

Fertile eggs obtained from specific-pathogen-free (SPF) Leghorn chickens (HY-Vac Laboratory Eggs, Co., Adel, Iowa) were incubated under standard conditions. Ten hatched chickens were randomly assigned to each of 12 Horsfall-Bauer isolation units and raised until they were 5 weeks of age. Bird density was 360 cm² per bird at 5 weeks. All chickens had *ad libitum* access to feed and water. Birds were fed standard Mississippi State pullet starter diets. All diets met or exceeded National Research Council (1994) recommendations. The isolation room was a negative pressure environment maintained at 25° C with a 12 hour light:12 hour dark cycle.

Bacteria

Pasteurella multocida X-73 (serotype 1) was obtained from the National Animal Disease Center, Ames, Iowa. *P. multocida* was grown in brain-heart infusion (BHI) broth (Difco Laboratories, Detroit, MI) at 37° C. After 16 hours incubation, 1 ml of culture was transferred to 100 ml of fresh BHI broth and incubated at 37° C for 4 hours. The bacterial culture was serially diluted with sterile water in 10-fold increments. Each dilution was plated on blood agar plates and the colonies counted after 24 hours incubation to determine the number of colony forming units (CFUs) (Wang, C., and Glisson, J. R. 1994, Identification of common antigens of serotype 1 and serotype 3 *Pasteurella multocida* in poultry expressed *in vivo*, *Avian Diseases* 38:334-340).

Pasteurella multocida P-1581, *Pasteurella multocida* ATCC 11039, *Pseudomonas aeruginosa* ATCC 27853, *Pseudomonas aeruginosa* PAO1, *Escherichia coli* ATCC 25922, *Enterobacter aerogenes*, *Enterobacter cloacae*, *Salmonella typhimurium*, *Staphylococcus aureus*, *Staphylococcus aureus* T-5706, and *Bacillus subtilis* were supplied from stock cultures by Dr. F. Champlin (Department of Biological Sciences, Mississippi State University) where they are maintained as reference organisms. Culture rehydration and cryoprotective maintenance conditions have been described previously (Darnell, K.R., Hart, M.E., and Champlin, F.R., 1987, Variability of

cell surface hydrophobicity among *Pasteurella multocida* somatic serotype and *Actinobacillus lignieresii* strains, *Journal of Clinical Microbiology* 25:67-71).

Preparation of Caprine Serum Fraction (CSF-I2)

Goat serum was fractioned by collecting that material which flowed through a dialysis membrane (Spectra Por) possessing a molecular weight cut-off of 6-8,000 daltons. The low molecular weight material (CSF-I2) was lyophilized to a powder and stored at -70° C, until reconstituted with water for use. CSF-I2 was determined to be 37.5% proteinaceous based on its nitrogen content.

Bacterial Susceptibility Assays

Caprine serum and its high (over 8,000 daltons) and low molecular weight (less than 8,000 daltons) subfractions (each at a protein concentration of 20 mg/mL) were assessed for antimicrobial activity against both gram positive and gram negative bacteria by performing disk agar diffusion assays as described in Hart, M.E., and Champlin, F.R., 1988, Susceptibility to hydrophobic molecules and phospholipid composition in *Pasteurella multocida* and *Actinobacillus lignieresii*, *Antimicrobial Agents and Chemotherapy* 32:1354-1359).

Antibiotic minimum inhibitory concentrations (MICs) were determined in Mueller-Hinton broth (Difco Laboratories, Detroit, MI) using the broth dilution method described previously (Darnell, K.R., Hart, M.E., and Champlin, F.R., 1987, Variability of cell surface hydrophobicity among *Pasteurella multocida* somatic serotype and *Actinobacillus lignieresii* strains, *Journal of Clinical Microbiology* 25:67-71).

Caprine serum and its dialysate containing immunoglobulins (over 8,000 daltons) were unable to inhibit bacterial growth. CSF-I2, material presumed to contain small molecular weight immunostimulatory agents, also failed to inhibit the growth of all test bacteria, including two serotypes of *Pasteurella* (Table I).

Table I.

Susceptibility Of Selected Bacteria To Growth Inhibition By Caprine Serum Fractionated Into Its High (>8,000 Daltons) And Low (<8,000 Daltons) Molecular Weight Components.

Organism	^a Zone of Inhibition			
	Low MW		High MW	
	4 hr	24 hr	4 hr	24 hr
Gram Negative Bacteria				
<i>Pseudomonas aeruginosa</i> ATCC 27853	0	0	0	0
<i>Pseudomonas aeruginosa</i> PAO1	0	0	0	0
<i>Escherichia coli</i> ATCC 25922	0	0	0	0
<i>Enterobacter aerogenes</i>	0	0	0	0
<i>Enterobacter cloacae</i>	0	0	0	0
<i>Salmonella typhimurium</i>	0	0	0	0
<i>Pasteurella multocida</i> ATCC 11039	^b IG	0	IG	0
<i>Pasteurella multocida</i> P-1581	IG	0	IG	0
Gram Positive Bacteria				
<i>Staphylococcus aureus</i>	0	0	0	0
<i>Staphylococcus aureus</i> T-5706	0	0	0	0
<i>Bacillus subtilis</i>	IG	0	IG	0

^aMHA plates were streak inoculated with each of the assay organisms. Sterile filter paper disks impregnated with either the high or low MW caprine serum fraction were aseptically applied to the seeded plate surfaces. The plates were incubated for 24 h at 37 °C, during which time inhibition of growth in areas surrounding the disks were visually assessed at 4 and 24 hr.

^bIG, insufficient growth.

Bird Treatment

Two of 12 housing units were utilized as stress control pens. Birds assigned to these units did not receive a bacterial challenge or CSF-I2, but were sham handled in a manner consistent with all other birds. All inoculated birds received 18-30 colony forming units

LAW OFFICES OF

SERLE IAN MOSOFF
303 BOSTON POST ROAD
PORT CHESTER, NEW YORK 10573
(914) 939-1300

1 (CFUs) of *Pasteurella multocida* (X-73 strain, serotype 1) on Day 0. CSF-I2 and sham
2 treatments, as well as bacterial challenges, were administered as 0.5 ml intramuscular
3 injections.

4 Control birds housed in 5 of the remaining 10 units received *Pasteurella* and sham
5 treatment in a manner consistent with CSF-I2 treated birds. In experiment 1, treated birds
6 were given 0.5 ml of a 10 mg/ml CSF-I2 solution (5 mg) on Days -1 and 0. In the second
7 experiment the treated birds received 0.5 ml of a 20 mg/ml CSF-I2 solution (10 mg) on
8 Days -1 and 0. Treated birds in the third experiment received 0.5 ml of a 20 mg/ml CSF-I2
9 solution (10 mg) on Days -1, 0, and +1. The number of deaths were recorded and dead
10 birds were removed from each unit at the same time each day. Each experiment utilized a 7
11 day trial period.

12 ***Flow Cytometry***

13 Birds used in Experiment 3 were banded for identification. Five birds were selected
14 at random from both the control and CSF-I2 treated populations. Two ml of blood was
15 drawn from a wing vein and immediately processed for CD4 and CD8 counts. Blood was
16 drawn 1 wk prior to the *Pasteurella* challenge in order to establish a representative baseline
17 count. Blood was also collected on Day 1 in order to assess how the challenge and CSF-I2
18 treatment may alter these immunological parameters.

19 The CD4 and CD8 lymphocyte subset percentages in the peripheral blood were
20 enumerated using a modification of a previously published method (Ainsworth, A.J.,
21 Dexiang, C., and Greenway, T., 1990, Characterization of monoclonal antibodies to channel
22 catfish, *Ictalurus punctatus*, Vet. Immunol. Immunopathol. 26:81-92). Briefly, Ficoll-Paque
23 isolated peripheral blood leukocytes were incubated with FITC-conjugated mouse anti-
24 chicken CD4 or RPE-conjugated mouse anti-chicken CD8, or the appropriate isotype-
25 matched control conjugates (Southern Biotechnology Associates, Inc., Birmingham, AL).
26 Modifications to the procedure included a reduction of the incubation times to 5 minutes
27 and analysis of samples using a FACSCalibur flow cytometer (Becton Dickinson, San Jose,
28 CA).

29 ***Differential Cell Counts***

30 A total of 200 nonerythroid, nonthrombocytic leukocytes were counted on duplicate
31 blood smears stained with Wright's stain (Sigma Chemical Co., St. Louis, MO). The

LAW OFFICES OF

SERLE IAN MOSOFF
303 BOSTON POST ROAD
PORT CHESTER, NEW YORK 10573
(914) 939-1300

lymphocytes, heterophils, monocytes, eosinophils, and basophils were identified by the morphological characteristics described by Lucas, A.M., and Jamroz, C., Atlas of avian hematology, United States Department of Agriculture, Agriculture Monograph 25, Washington, D.C. 1961).

Statistical Analysis

All experimental protocols required a completely randomized design to be followed. Data demonstrating cumulative mortality and diagnostic blood parameters were analyzed by a one way analysis of variance and the means separated by Fisher's projected LSD procedure (SAS Package). A p value less than 0.05 had to be reached in order to be considered significant.

Results

Birds receiving the 5 mg CSF-I2 treatment regime on Days -1 and 0 demonstrated significantly less mortality than inoculated controls throughout the study period (Figure 1). However, the greatest difference was observed within the first 48 hours after challenge. During this 2 day period, the control group receiving 30 CFUs of *P. multocida* displayed the greatest mortality. Forty-nine percent of the control population were dead after 24 hours and 91% were dead by Day 2. The 5 mg CSF-I2 treatment regime, however, significantly retarded pathogenesis of the *Pasteurella* infection. Mortality in CSF-I2 treated birds were 6 and 56% on Days 1 and 2, respectively. Mortality gradually increased to 78% over the following 5 days of the study period.

Pathogenesis was retarded further when the CSF-I2 dose regime was doubled to 10 mg (Figure 2).

A *Pasteurella* challenge of 18 CFUs caused rapid mortality in the control population (60% and 80% for Days 1 and 2, respectively). Mortality in the corresponding CSF-I2 treated group was only 0 and 13% on Days 1 and 2, respectively. Mortality on Day 7 had risen to 33%, which was significantly less than that of the control population (83%), and was less than that observed when the 5 mg CSF-I2 treatment regime was used.

The 10 mg CSF-I2 treatment regime was extended to include an additional delivery dose on Day 1 (after the daily observation). Twenty-eight CFUs of *Pasteurella* were used to initiate pathogenesis. After 24 h, mortality in the CSF-I2 treated population was significantly less than that of the control population (12% and 77%, respectively; Figure 3).

LAW OFFICES OF

SERLE IAN MOSOFF
303 BOSTON POST ROAD
PORT CHESTER, NEW YORK 10573
(914) 939-1300

1 Mortality on Days 2 and 7 in CSF-I2 treated birds (38% and 56%, respectively) were
2 consistently lower than that found in the corresponding untreated control population (94%
3 and 97%, respectively).

4 Both treatment regimes utilizing 10 mg of CSF-I2 allowed birds to survive the
5 bacterial challenge better than the 5 mg CSF-I2 treatment regime (Figure 4). There was no
6 evidence, however, which showed that the additional administration of CSF-I2 on Day 1
7 initiated a significantly better response than the 2 day dose regime of 10 mg CSF-I2.

8 The blood levels of CD4 and CD8 cells in unchallenged SPF chickens of Trial 3
9 were 18 and 26%, respectively. The microbial challenge caused the Day 1 CD4 cell count to
10 decrease to 10%. Birds treated with CSF-I2, however, expressed a CD4 cell count of 21%.
11 There were no appreciable changes in CD8 levels due to CSF-I2 treatment. Differences
12 cannot be considered significant at this time because the sample size (and the high death
13 rate which made it impractical to follow the same birds) did not permit this determination.

14 I claim:

- 15 1. The use of a composition of matter comprising the substantially immunoglobulin
16 free, peptide containing portion of the blood of a mammal which passes through a
17 dialysis membrane having a molecular weight cut-off of no greater than 60,000
18 daltons to stimulate the disease fighting systems of a non-mammalian vertebrate.
- 19 2. The use of the composition of matter of claim 1 wherein the membrane has a
20 molecular weight cut-off of no greater than 25,000 daltons.
- 21 3. The use of the composition of matter of claim 1 wherein the membrane has a
22 molecular weight cut-off of no greater than 8,000 daltons.
- 23 4. The use of the composition of matter of claim 1 wherein the non-mammalian
24 vertebrate is a reptile, fish, bird or amphibian.
- 25 5. The use of the composition of matter of claim 1 wherein the non-mammalian
26 vertebrate is a fish.
- 27 6. The use of the composition of claim 1 wherein the non-mammalian vertebrate is a
28 bird.
- 29 7. The use of the composition of claim 6 wherein the bird is a chicken or turkey.

LAW OFFICES OF

SERLE IAN MOSOFF
303 BOSTON POST ROAD
PORT CHESTER, NEW YORK 10573
(914) 939-1300

- 1 8. The use of the composition of matter of claim 1 to stimulate the disease fighting
2 systems of a bird against a challenge by *Pasteurella multocida*.
3
4

005760-6009950

LAW OFFICES OF

SERLE IAN MOSOFF
303 BOSTON POST ROAD
PORT CHESTER, NEW YORK 10573
(914) 939-1300

1
2
3
4
5
6
7

Abstract


This invention relates to compositions utilized to modulate the immune system of non-mammalian vertebrates. More particularly, the present invention relates to the use of low molecular weight substantially immunoglobulin free fractions isolated from mammals to induce a stimulated immune response in non-mammalian vertebrates.

006760 6009990

LAW OFFICES OF

SERLE IAN MOSOFF
303 BOSTON POST ROAD
PORT CHESTER, NEW YORK 10573
(914) 939-1300

Figure 1



005750" 60099960

Figure 2






Figure 3



005750" 60099960

Figure 4



COMBINED DECLARATION AND POWER OF ATTORNEY

As below named inventors, we hereby declare that:

TYPE OF DECLARATION

This declaration is of the following type:

<input checked="" type="checkbox"/>	original
<input type="checkbox"/>	design
<input type="checkbox"/>	supplemental
<input type="checkbox"/>	national state of PCT
<input type="checkbox"/>	divisional
<input type="checkbox"/>	continuation
<input type="checkbox"/>	continuation-in-part (CIP)

INVENTORSHIP IDENTIFICATION

My residence, post office address and citizenship is as stated below next to my name, I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

TITLE OF INVENTION

COMPOSITION AND METHOD FOR IMMUNOMODULATION IN NON-MAMMALIAN VERTEBRATES

SPECIFICATION IDENTIFICATION

the specification of which:

<input checked="" type="checkbox"/>	is attached hereto.
<input type="checkbox"/>	was filed on _____ as Serial No. _____ or Express Mail No., as Serial No. _____ not yet known _____ and was amended on _____ (if applicable).
<input type="checkbox"/>	was described and claimed in PCT International Appln. No. _____ filed on _____ and as amended under PCT Article 19 on _____ (if any).

ACKNOWLEDGEMENT OF REVIEW OF PAPERS AND DUTY OF CANDOR

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations. s 1.56(a).

☐

In compliance with this duty there is attached an information disclosure statement. 37CFR 1.97.

PRIORITY CLAIM

I hereby claim foreign priority benefits under Title 35, United States Code, 119 of any foreign application(s) for patent or inventor's certificate or of any PCT international application(s) designating at least one country other than the United States of America listed below and have also identified below any foreign application(s) for patent or inventor's certificate or any PCT international application(s) designating at least one country other than the United States of America filed by me on the same subject matter having a filing date before that of the application(s) of which priority is claimed.

☒

no such applications have been filed.
such applications have been filed as follows:

EARLIEST FOREIGN APPLICATION(S), IF ANY FILED WITHIN 12 MONTHS
(6 MONTHS FOR DESIGN) PRIOR TO THIS U.S. APPLICATION

Country Application No. Date of Filing Priority Claimed Under 37 USC 119

ALL FOREIGN APPLICATION(S), IF ANY FILED MORE THAN 12 MONTHS
(6 MONTHS FOR DESIGN) PRIOR TO THIS U.S. APPLICATION

Country Application No. Date of Filing Priority Claimed Under 37 USC 119

POWER OF ATTORNEY

As a named inventor, I hereby appoint the following attorneys to prosecute this application and transact all business in the Patent and Trademark Office connected therewith.

Serle Ian Mosoff, Esq.
Reg. No. 25,900

Send Correspondence To:

Direct Telephone Calls To:


Serle Ian Mosoff
Law Offices at Sound Shore
303 Boston Post Road
Port Chester, NY 10573

(914) 939-1300

DECLARATION

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

SIGNATURE(S)

<i>Full Name of Sole or First Inventor</i> Daniel R. Ansley	<i>Citizenship</i> USA
<i>RESIDENCE Address-Street</i> 404 S. Maple Street	<i>POST OFFICE Address-Street</i> 404 S. Maple Street
<i>City (Zip)</i> Ottawa 66067	<i>City (Zip)</i> Ottawa 66067
<i>State or Country</i> Kansas	<i>State or Country</i> Kansas
<i>Date</i> 9-1-2000	<i>Signature</i> 

LAW OFFICES AT SOUND SHORE
303 BOSTON POST ROAD
PORT CHESTER, NEW YORK 10573
(914) 939-1300

005760-6009950

<i>Full Name of Second Joint Inventor</i> Kenneth O. Willeford	<i>Citizenship</i> USA
<i>RESIDENCE Address-Street</i> 215 B Helen Circle	<i>POST OFFICE Address-Street</i> 215 B Helen Circle
<i>City (Zip)</i> Starkville 39759	<i>City (Zip)</i> Starkville 39759
<i>State or Country</i> Mississippi	<i>State or Country</i> Mississippi
<i>Date</i>	<i>Signature</i>

<i>Full Name of Third Joint Inventor</i>	<i>Citizenship</i>
<i>RESIDENCE Address-Street</i>	<i>POST OFFICE Address-Street</i>
<i>City (Zip)</i>	<i>City (Zip)</i>
<i>State or Country</i>	<i>State or Country</i>
<i>Date</i>	<i>Signature</i>

CHECK PROPER BOX(ES) FOR ANY OF THE FOLLOWING ADDED PAGE(S)
WHICH FORM A PART OF THIS DECLARATION

- ☐ Signature for fourth and subsequent joint inventors. Number of pages added: _____
- ☐ Signature by administrator(trix), executor(trix) or legal representative for deceased or incapacitated inventor. Number of pages added: _____
- ☐ Signature for inventor who refuses to sign or cannot be reached by person authorized under 37 CFR 1.47. Number of pages added: _____
- ☐ Added pages to combined declaration and power of attorney for divisional, continuation, or continuation- in-part (CIP) application. Number of pages added: _____

If no further pages form a part of this Declaration then end this Declaration with this page and check the following item

- ☒ This declaration ends with this page.

COMBINED DECLARATION AND POWER OF ATTORNEY

As below named inventors, we hereby declare that:

TYPE OF DECLARATION

This declaration is of the following type:

- | | |
|--|----------------------------|
| <input checked="checked" type="checkbox"/> | original |
| <input type="checkbox"/> | design |
| <input type="checkbox"/> | supplemental |
| <input type="checkbox"/> | national state of PCT |
| <input type="checkbox"/> | divisional |
| <input type="checkbox"/> | continuation |
| <input type="checkbox"/> | continuation-in-part (CIP) |

INVENTORSHIP IDENTIFICATION

My residence, post office address and citizenship is as stated below next to my name, I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

TITLE OF INVENTION

COMPOSITION AND METHOD FOR IMMUNOMODULATION IN NON-MAMMALIAN VERTEBRATES

SPECIFICATION IDENTIFICATION

the specification of which:

- | | |
|--|---|
| <input checked="checked" type="checkbox"/> | is attached hereto. |
| <input type="checkbox"/> | was filed on _____ as Serial No. _____ or Express Mail No., as Serial No. _____ not yet known _____ and was amended on _____ (if applicable). |
| <input type="checkbox"/> | was described and claimed in PCT International Appln. No. _____ filed on _____ and as amended under PCT Article 19 on _____ (if any). |

ACKNOWLEDGEMENT OF REVIEW OF PAPERS AND DUTY OF CANDOR

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations. s 1.56(a).

☐ In compliance with this duty there is attached an information disclosure statement. 37CFR 1.97.

PRIORITY CLAIM

I hereby claim foreign priority benefits under Title 35, United States Code, 119 of any foreign application(s) for patent or inventor's certificate or of any PCT international application(s) designating at least one country other than the United States of America listed below and have also identified below any foreign application(s) for patent or inventor's certificate or any PCT international application(s) designating at least one country other than the United States of America filed by me on the same subject matter having a filing date before that of the application(s) of which priority is claimed.

☒ no such applications have been filed.
☐ such applications have been filed as follows:

EARLIEST FOREIGN APPLICATION(S), IF ANY FILED WITHIN 12 MONTHS
(6 MONTHS FOR DESIGN) PRIOR TO THIS U.S. APPLICATION

Country Application No. Date of Filing Priority Claimed Under 37 USC 119

ALL FOREIGN APPLICATION(S), IF ANY FILED MORE THAN 12 MONTHS
(6 MONTHS FOR DESIGN) PRIOR TO THIS U.S. APPLICATION

Country Application No. Date of Filing Priority Claimed Under 37 USC 119

POWER OF ATTORNEY

As a named inventor, I hereby appoint the following attorneys to prosecute this application and transact all business in the Patent and Trademark Office connected therewith.

Serle Ian Mosoff, Esq.
Reg. No. 25,900

Send Correspondence To:

Direct Telephone Calls To:

Serle Ian Mosoff
Law Offices at Sound Shore
303 Boston Post Road
Port Chester, NY 10573

(914) 939-1300

DECLARATION

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

SIGNATURE(S)

<i>Full Name of Sole or First Inventor</i> Daniel R. Ansley	<i>Citizenship</i> USA
<i>RESIDENCE Address-Street</i> 404 S. Maple Street	<i>POST OFFICE Address-Street</i> 404 S. Maple Street
<i>City (Zip)</i> Ottawa 66067	<i>City (Zip)</i> Ottawa 66067
<i>State or Country</i> Kansas	<i>State or Country</i> Kansas
<i>Date</i>	<i>Signature</i>

LAW OFFICES AT SOUND SHORE
303 BOSTON POST ROAD
PORT CHESTER, NEW YORK 10573
(914) 939-1300

Full Name of Second Joint Inventor <i>Kenneth O. Willeford</i>	Citizenship <i>USA</i>
RESIDENCE Address-Street <i>215 B Helen Circle</i>	POST OFFICE Address-Street <i>215 B Helen Circle</i>
City (Zip) <i>Starkville 39759</i>	City (Zip) <i>Starkville 39759</i>
State or Country <i>Mississippi</i>	State or Country <i>Mississippi</i>
Date <i>Sept 4, 2000</i>	Signature <i>Kenneth O. Willeford</i>
Full Name of Third Joint Inventor	Citizenship
RESIDENCE Address-Street	POST OFFICE Address-Street
City (Zip)	City (Zip)
State or Country	State or Country
Date	Signature

CHECK PROPER BOX(ES) FOR ANY OF THE FOLLOWING ADDED PAGE(S)
WHICH FORM A PART OF THIS DECLARATION

- ☐ Signature for fourth and subsequent joint inventors. Number of pages added: _____
- ☐ Signature by administrator(trix), executor(trix) or legal representative for deceased or incapacitated inventor. Number of pages added: _____
- ☐ Signature for inventor who refuses to sign or cannot be reached by person authorized under 37 CFR 1.47. Number of pages added: _____
- ☐ Added pages to combined declaration and power of attorney for divisional, continuation, or continuation- in-part (CIP) application. Number of pages added: _____

If no further pages form a part of this Declaration then end this Declaration with this page and check the following item

- ☒ This declaration ends with this page.